<DOC>
	<DOC>NCT02180958</DOC>
	<brief_summary>The main objective of this study is to assess the safety at 1 month after any embolization session and the efficacy at: - 12 months post last embolization in case of treatment with embolization only - 12 months after additional treatment with neurosurgery - 36 months after additional treatment with radiosurgery</brief_summary>
	<brief_title>ONYX Evaluation in the Endovascular Treatment of Cerebral Arteriovenous Malformations (cAVM)</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
	<criteria>The patient presents a cerebral AVM (not already treated) that can be treated by embolization with Onyx whether or not associated with a cyanoacrylate based adhesive, The patient is at least 6 years old. During the treatment period for his/her cerebral AVM, the patient participates in a study assessing another medical device, another procedure or a drug. The patient and/or his/her legal representative (if applicable) refuses to give his/her consent to the collection and processing of data required by the centralized followup. For patients who refused collection of their personal data, only, the reason for non inclusion and date of implantation will be documented. Any condition that could prevent followup of the patient.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cerebral arteriovenous malformations</keyword>
	<keyword>cAVM</keyword>
	<keyword>ONYX</keyword>
</DOC>